Hindmarch I
University of Surrey, Department of Human Psychopharmacology, Milford Hospital, Godalming, UK.
Eur Neuropsychopharmacol. 1997 Apr;7 Suppl 1:S17-21; discussion S71-3. doi: 10.1016/s0924-977x(97)00416-1.
This review assesses the relative efficacy and side-effect profile of the currently available treatment options for major depression and the new selective noradrenergic agent, reboxetine. The effects of these treatments on psychomotor function are reviewed using: choice reaction time (CRT) and critical flicker fusion threshold (CFFT) measurements to compare and contrast the various antidepressants. Tricyclic antidepressant (TCA) agents are associated with an increased risk of accidents, especially in the elderly (primarily accidents related to driving or falls/fractures due to postural hypotension). In comparison, the newer noradrenergic agents such as reboxetine have demonstrated significant improvements in the incidence and severity of effects on psychomotor function. Such a lack of side-effects makes agents like reboxetine most useful for the treatment of depression in ambulant patients performing their usual activities of daily living.
本综述评估了目前可用于治疗重度抑郁症的各种疗法以及新型选择性去甲肾上腺素能药物瑞波西汀的相对疗效和副作用情况。通过选择反应时间（CRT）和临界闪烁融合阈值（CFFT）测量来回顾这些疗法对精神运动功能的影响，以比较和对比各种抗抑郁药。三环类抗抑郁药（TCA）会增加意外事故风险，尤其是在老年人中（主要是与驾驶相关的事故或因体位性低血压导致的跌倒/骨折）。相比之下，新型去甲肾上腺素能药物如瑞波西汀已显示出在精神运动功能影响的发生率和严重程度方面有显著改善。这种副作用的缺乏使得像瑞波西汀这样的药物对于正在进行日常活动的门诊患者治疗抑郁症最为有用。
